JP2016534717A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534717A5 JP2016534717A5 JP2016524494A JP2016524494A JP2016534717A5 JP 2016534717 A5 JP2016534717 A5 JP 2016534717A5 JP 2016524494 A JP2016524494 A JP 2016524494A JP 2016524494 A JP2016524494 A JP 2016524494A JP 2016534717 A5 JP2016534717 A5 JP 2016534717A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- chimeric receptor
- cell
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892218P | 2013-10-17 | 2013-10-17 | |
| US61/892,218 | 2013-10-17 | ||
| US201462026243P | 2014-07-18 | 2014-07-18 | |
| US62/026,243 | 2014-07-18 | ||
| PCT/US2014/060999 WO2015058018A1 (en) | 2013-10-17 | 2014-10-17 | Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016534717A JP2016534717A (ja) | 2016-11-10 |
| JP2016534717A5 true JP2016534717A5 (enExample) | 2017-11-24 |
| JP6417413B2 JP6417413B2 (ja) | 2018-11-07 |
Family
ID=52828713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524494A Active JP6417413B2 (ja) | 2013-10-17 | 2014-10-17 | 多様な腫瘍に対する抗体依存性細胞毒性を誘発するキメラ受容体 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3057986B1 (enExample) |
| JP (1) | JP6417413B2 (enExample) |
| KR (1) | KR102308597B1 (enExample) |
| CN (1) | CN105683214B (enExample) |
| AU (1) | AU2014337195B2 (enExample) |
| BR (1) | BR112016007695A2 (enExample) |
| CA (1) | CA2926267C (enExample) |
| IL (1) | IL245088A0 (enExample) |
| SG (1) | SG11201602979RA (enExample) |
| WO (1) | WO2015058018A1 (enExample) |
| ZA (1) | ZA201602798B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101520534B1 (ko) | 2012-05-07 | 2015-05-21 | 고려대학교 산학협력단 | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 |
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| WO2016040441A1 (en) * | 2014-09-09 | 2016-03-17 | Unum Therapeutics | Chimeric receptors and uses thereof in immune therapy |
| WO2016177682A1 (en) | 2015-05-06 | 2016-11-10 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
| EP4289944A3 (en) * | 2015-10-08 | 2024-03-13 | National University Corporation Tokai National Higher Education and Research System | Method for preparing genetically-modified t cells which express chimeric antigen receptor |
| MY201637A (en) * | 2015-10-15 | 2024-03-06 | Celularity Inc | Natural killer cells and ilc3 cells and uses thereof |
| GB201602974D0 (en) * | 2016-02-19 | 2016-04-06 | Clube Jasper R | Engineered cells & methods (1) |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| WO2018017649A1 (en) * | 2016-07-19 | 2018-01-25 | Unum Therapeutics Inc. | Use of antibody-coupled t cell receptor (actr) with multiple anti-cancer antibodies in cancer treatment |
| EP3315511A1 (en) | 2016-10-29 | 2018-05-02 | Miltenyi Biotec GmbH | Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens |
| CN118581046A (zh) | 2016-11-22 | 2024-09-03 | 新加坡国立大学 | 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| WO2019056174A1 (zh) * | 2017-09-19 | 2019-03-28 | 中山大学 | 一种过表达cxcr5的间质干细胞及其制备方法和用途 |
| CN115710576A (zh) | 2018-02-01 | 2023-02-24 | Nkmax有限公司 | 产生天然杀伤细胞的方法和用于治疗癌症的组合物 |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2019222642A1 (en) * | 2018-05-18 | 2019-11-21 | Senti Biosciences, Inc. | Engineered immune cells and methods of use |
| CN112512573B (zh) * | 2018-05-23 | 2026-02-27 | 百提威生技股份有限公司 | 双特异性t细胞衔接蛋白及其用途 |
| WO2020010110A1 (en) | 2018-07-03 | 2020-01-09 | Unum Therapeutics Inc. | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof |
| WO2020037066A1 (en) | 2018-08-14 | 2020-02-20 | Unum Therapeutics Inc. | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof |
| WO2020044239A1 (en) | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| EP3620464A1 (en) | 2018-09-10 | 2020-03-11 | Miltenyi Biotec GmbH | Car cell having crosslinked disulfide bridge on antigen recognizing moiety |
| US11851663B2 (en) | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| WO2020201527A1 (en) | 2019-04-04 | 2020-10-08 | Umc Utrecht Holding B.V. | Modified immune receptor constructs |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| WO2021047804A1 (en) | 2019-09-11 | 2021-03-18 | Miltenyi Biotec B.V. & Co. KG | In vitro method for transduction of t cells in the presence of malignant cells |
| EP3875478A1 (en) | 2020-03-05 | 2021-09-08 | Canvax Biotech, S.L. | Novel non-immunogenic chimeric antigen receptors and uses thereof |
| EP3878464A1 (en) | 2020-03-09 | 2021-09-15 | Miltenyi Biotec B.V. & Co. KG | Use of a car cell having crosslinked disulfide bridge on antigen recognizing moiety for targeting cancer cells |
| CN113583139A (zh) * | 2020-07-06 | 2021-11-02 | 上海鑫湾生物科技有限公司 | 一种嵌合受体及其应用 |
| AU2022249039A1 (en) * | 2021-03-30 | 2023-09-28 | The Regents Of The University Of California | Transplanted cell protection via modified fc receptors |
| MX2024004009A (es) | 2021-09-27 | 2024-06-19 | Sotio Biotech Inc | Polipéptidos receptores quiméricos en combinación con moléculas transmetabólicas que redirigen metabolitos de glucosa fuera de la vía de la glucólisis y usos terapéuticos de estos. |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| US20260053924A1 (en) | 2022-08-19 | 2026-02-26 | Sotio Biotech Inc. | Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof |
| WO2024040207A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
| US5124263A (en) | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| AU7477394A (en) | 1993-07-30 | 1995-03-27 | University Of Medicine And Dentistry Of New Jersey | Efficient gene transfer into primary lymphocytes |
| CA2487932A1 (en) * | 2002-05-30 | 2003-12-11 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20110123440A1 (en) | 2005-03-29 | 2011-05-26 | Genevieve Hansen | Altered Antibody FC Regions and Uses Thereof |
| US20080003225A1 (en) * | 2006-06-29 | 2008-01-03 | Henri Vie | Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors |
| AU2008281801A1 (en) * | 2007-08-01 | 2009-02-05 | Glaxo Group Limited | Novel antibodies |
| US8067339B2 (en) * | 2008-07-09 | 2011-11-29 | Merck Sharp & Dohme Corp. | Surface display of whole antibodies in eukaryotes |
| DE102009013748B4 (de) * | 2009-03-17 | 2012-01-26 | Paul-Ehrlich-Institut | Bestimmung von Interaktionen konstanter Antikörperteile mit Fc-gamma Rezeptoren |
| JP5934099B2 (ja) * | 2009-10-01 | 2016-06-15 | アメリカ合衆国 | 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用 |
| US20140072983A1 (en) * | 2010-08-10 | 2014-03-13 | Amgen Inc. | Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2016040441A1 (en) * | 2014-09-09 | 2016-03-17 | Unum Therapeutics | Chimeric receptors and uses thereof in immune therapy |
-
2014
- 2014-10-17 KR KR1020167012468A patent/KR102308597B1/ko active Active
- 2014-10-17 SG SG11201602979RA patent/SG11201602979RA/en unknown
- 2014-10-17 JP JP2016524494A patent/JP6417413B2/ja active Active
- 2014-10-17 BR BR112016007695A patent/BR112016007695A2/pt not_active IP Right Cessation
- 2014-10-17 WO PCT/US2014/060999 patent/WO2015058018A1/en not_active Ceased
- 2014-10-17 CA CA2926267A patent/CA2926267C/en active Active
- 2014-10-17 EP EP14854582.5A patent/EP3057986B1/en active Active
- 2014-10-17 AU AU2014337195A patent/AU2014337195B2/en active Active
- 2014-10-17 CN CN201480057323.2A patent/CN105683214B/zh active Active
-
2016
- 2016-04-13 IL IL245088A patent/IL245088A0/en unknown
- 2016-04-22 ZA ZA2016/02798A patent/ZA201602798B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014337195B2 (en) | Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors | |
| JP2017515506A5 (enExample) | ||
| FI3909972T3 (fi) | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä | |
| JP7382829B2 (ja) | キメラ抗原受容体を発現するｔ細胞 | |
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| FI4324851T3 (fi) | BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä | |
| JP2016520074A5 (enExample) | ||
| RU2017130985A (ru) | Фармацевтическая композиция и способ снижения ингибирующего эффекта pd-l1 на т-клетки человека | |
| JP2017513478A5 (enExample) | ||
| RU2016143155A (ru) | Cd33-специфические химерные антигенные рецепторы для иммунотерапии рака | |
| IL311608A (en) | Preparations and methods for the selective elimination and replacement of hematopoietic stem cells | |
| RU2017129455A (ru) | Сконструированные иммунные клетки с нокаутом рецептора т-клеток, снабженные химерными антигенными рецепторами, связывающимися с cd123, для лечения рецедивирующего/устойчивого острого миелоидного лейкоза или новообразования из бластных плазмоцитоидных дендритных клеток | |
| JP2017515464A5 (enExample) | ||
| JP2018029594A5 (enExample) | ||
| AU2017384900A1 (en) | Chimeric antigen receptor and natural killer cells expressing same | |
| RU2017102769A (ru) | EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА | |
| JP2014533928A5 (enExample) | ||
| JP2020513754A5 (enExample) | ||
| RU2016143381A (ru) | Способ и композиции для клеточной иммунотерапии | |
| JP2018518990A5 (enExample) | ||
| JP2017537627A5 (enExample) | ||
| JP2018529327A5 (enExample) | ||
| JP2017537622A5 (enExample) | ||
| JP2016514462A5 (enExample) | ||
| JP2017518071A5 (enExample) |